Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Curosurf in hospitalized patients with COVID-19 ARDS
2020-002632-75Phase 2Unknown
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Jun 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Poractant alfa in acute respiratory distress syndrome (ARDS) and coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoint: Ventilator-free days. Status: unknown.
02
Drugs
Poractant alfa
03
Conditions
acute respiratory distress syndrome (ARDS)coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-002632-75.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002632-75.